Marina Biotech, Inc. MRNA today announced the completion of dosing for Cohort 1 in the Dose Escalation Phase of its START-FAP clinical trial with CEQ508. The first three patients received the starting dose of 1x10(8) colony forming units (cfu)/day for up to 28 days of continuous oral dosing.
Patients were monitored by study staff on a daily basis with the primary study endpoint of determining safety and tolerability of CEQ508 in patients with FAP. Dosing of Cohort 2 is expected to begin in July 2011 with each patient in the cohort receiving a dose of 1x10(9) cfu/day for up to 28 days.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in